The benefits of Champix^® as a smoking-cessation medicine outweigh the reported slight increase in cardiovascular events. The European Medicines Agency has confirmed that the benefit-risk balance for Champix^® (varenicline) remains positive, despite the results of a recent meta-analysis on cardiovascular side effects of the medicinal product.

risk information - full text (available in German only)